Compare PLX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLX | PEPG |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 179.4M |
| IPO Year | 1996 | 2022 |
| Metric | PLX | PEPG |
|---|---|---|
| Price | $2.56 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.19 |
| AVG Volume (30 Days) | 836.2K | ★ 936.2K |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.65 | $1.31 |
| 52 Week High | $3.19 | $7.80 |
| Indicator | PLX | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 45.94 |
| Support Level | $2.21 | $2.24 |
| Resistance Level | $2.75 | $2.62 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 19.67 | 32.20 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.